with Franchise med spa business · Leading multi-site med spa franchise
LenderHawk analysis. Not affiliated with or endorsed by Acquisitions Anonymous.
Med spa businesses can look recurring because Botox patients often return every three months, but the recurring value depends on retaining individual injectors.
A two-location med spa with a third territory to build is not automatically a growth story; it may also signal unfinished obligations and capital needs.
When the seller is also the injector, customer retention risk rises because clients frequently follow the person who performs the treatment.
A business can have strong topline growth and still deserve a discount if one location is carrying the operation and the second location is weaker.
MSO ownership structures can make SBA execution harder because banks may want physician guarantees that non-physician buyers cannot provide.
The attractiveness of med spas in a downturn comes from the lipstick-effect dynamic: consumers may cut other expenses before cutting appearance-related spending.
A 5x SDE multiple can be too rich if the business has person-dependence, expansion obligations, and uncertain transferability.
Buying a med spa often works better when the first acquisition is a strong platform and growth comes from de novo clinics rather than overpaying for multiple sites.
Beauty and appearance spending can remain resilient, or even improve, during downturns because consumers keep discretionary self-care that makes them feel better or more presentable.
When to use: Use this lens when evaluating consumer-facing aesthetic or beauty businesses in recession-risk environments.
Acquire one strong, well-located platform business first, then expand by opening new locations rather than overpaying for a multi-site bundle with uneven performance.
When to use: Use this framework when a service franchise can scale by copying a profitable location into new markets.
The listing asked $4 million on just over $3 million of gross revenue and $813,000 of cash flow.
Connor reads the broker teaser and the panel evaluates the implied valuation.
The listing was established in 2022 and already had two operating locations plus a third territory available.
The hosts discuss whether the business is truly scaled or still early in its growth cycle.
One location was about 2,100 square feet with triple-net rent of $5,700 per month, while the second was about 1,200 square feet and a sublease.
The hosts use the occupancy details to infer that the second location may be weaker.
Botox is treated as recurring revenue because typical treatment cadence is about every three months.
Bill explains why recurring injectable revenue matters more than one-time services.
The med spa growth forecast cited in the episode was 14% CAGR from 2024 to 2030.
The panel discusses industry growth assumptions and where future demand may come from.
Only about 5% of the U.S. population has gotten Botox, with another 3% strongly considering it.
Bill cites figures from a separate industry video he made to explain adoption potential.
Heather said only about 3% of med spas were private-equity-owned as of late last year.
The hosts argue that the category remains fragmented despite growing investor interest.
The hosts said med spas often run around 60% gross margins, though the exact figure varies by operator and product mix.
They compare margin performance to a prior med spa deal they had reviewed.
Verify which location is truly driving the earnings before underwriting the deal.
Why: A strong flagship can hide a weaker second site that needs more capital or management attention.
Map the obligation and cost to develop the third territory before agreeing to the asking price.
Why: An available territory may be a required build-out, not optional upside.
Treat seller-operator injectors as key-person assets and build retention protections into the structure.
Why: Patients often follow the injector, so losing that person can quickly erode revenue.
Assume SBA approval is not automatic when the buyer would need an MSO structure.
Why: Banks may require guarantees or get confused by the legal workaround, which can derail financing.
Push for a lower price if the business depends on a technician-owner and has a weaker second site.
Why: Person-dependence and uneven operations are real risks that should show up in the valuation.
Prefer acquiring one proven med spa and expanding with de novo sites rather than buying a multi-site bundle with mixed performance.
Why: The first path gives cleaner control over location economics and reduces the chance of paying for underperformance.
Michael recounts a dermatologist friend who quit performing Botox after seeing a cash-constrained patient spend her last $500 on injections she did not need, which made the work feel uncomfortable. The anecdote is used to explain why dermatology practices did not always embrace Botox treatment.
Lesson: High-margin procedures can still be unattractive to providers if the client behavior feels ethically or operationally difficult.